These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27075627)

  • 61. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 63. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
    Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
    Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer.
    Kim MS; Lee WS; Jeong J; Kim SJ; Jin W
    Oncotarget; 2015 Nov; 6(37):40158-71. PubMed ID: 26515594
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.
    Ma R; Karthik GM; Lövrot J; Haglund F; Rosin G; Katchy A; Zhang X; Viberg L; Frisell J; Williams C; Linder S; Fredriksson I; Hartman J
    J Natl Cancer Inst; 2017 Mar; 109(3):1-14. PubMed ID: 28376210
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
    Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
    Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
    [TBL] [Abstract][Full Text] [Related]  

  • 67. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
    Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
    Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
    [TBL] [Abstract][Full Text] [Related]  

  • 70. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
    Mori H; Kubo M; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Miyazaki T; Oda Y; Otsuka T; Nakamura M
    PLoS One; 2016; 11(12):e0167016. PubMed ID: 27977696
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
    Wang M; Liang L; Lei X; Multani A; Meric-Bernstam F; Tripathy D; Wu Y; Chen H; Zhang H
    Ann Diagn Pathol; 2018 Aug; 35():69-76. PubMed ID: 29843069
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer.
    Katsuta E; Yan L; Takeshita T; McDonald KA; Dasgupta S; Opyrchal M; Takabe K
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905596
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identification and functional analysis of 9p24 amplified genes in human breast cancer.
    Wu J; Liu S; Liu G; Dombkowski A; Abrams J; Martin-Trevino R; Wicha MS; Ethier SP; Yang ZQ
    Oncogene; 2012 Jan; 31(3):333-41. PubMed ID: 21666724
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.
    Menter T; Tzankov A
    Virchows Arch; 2019 Apr; 474(4):497-509. PubMed ID: 30132131
    [TBL] [Abstract][Full Text] [Related]  

  • 75. STAT3 and GR Cooperate to Drive Gene Expression and Growth of Basal-Like Triple-Negative Breast Cancer.
    Conway ME; McDaniel JM; Graham JM; Guillen KP; Oliver PG; Parker SL; Yue P; Turkson J; Buchsbaum DJ; Welm BE; Myers RM; Varley KE
    Cancer Res; 2020 Oct; 80(20):4355-4370. PubMed ID: 32816914
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PDJ amplicon in triple negative breast cancer.
    Roesler AS; Malasi S; Koslosky L; Hartmayer P; Naab TJ; Carter JM; Zahrieh D; Hillman D; Leon-Ferre RA; Couch FJ; Goetz MP; Anderson KS; Pockaj BA; Barrett MT
    Sci Rep; 2023 Jan; 13(1):618. PubMed ID: 36635351
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
    Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA
    Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948
    [TBL] [Abstract][Full Text] [Related]  

  • 78. RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple-negative breast cancer.
    El Shamieh S; Saleh F; Moussa S; Kattan J; Farhat F
    Pharmacogenomics; 2018 Jun; 19(9):757-760. PubMed ID: 29790419
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
    Reis LMD; Adamoski D; Ornitz Oliveira Souza R; Rodrigues Ascenção CF; Sousa de Oliveira KR; Corrêa-da-Silva F; Malta de Sá Patroni F; Meira Dias M; Consonni SR; Mendes de Moraes-Vieira PM; Silber AM; Dias SMG
    J Biol Chem; 2019 Jun; 294(24):9342-9357. PubMed ID: 31040181
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer.
    Long L; Fei X; Chen L; Yao L; Lei X
    Front Oncol; 2024; 14():1381251. PubMed ID: 38699644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.